Zacks Investment Research lowered shares of vTv Therapeutics Inc. (NASDAQ:VTVT) from a buy rating to a hold rating in a report issued on Tuesday morning.

According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

Several other brokerages have also commented on VTVT. Canaccord Genuity restated a buy rating and issued a $15.00 price objective on shares of vTv Therapeutics in a report on Friday, August 19th. HC Wainwright restated a buy rating on shares of vTv Therapeutics in a report on Tuesday, November 8th. Finally, Piper Jaffray Cos. restated an overweight rating and issued a $24.00 price objective on shares of vTv Therapeutics in a report on Saturday, October 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. vTv Therapeutics presently has an average rating of Buy and an average target price of $15.70.

vTv Therapeutics (NASDAQ:VTVT) opened at 5.32 on Tuesday. vTv Therapeutics has a 12-month low of $4.69 and a 12-month high of $7.70. The firm has a 50-day moving average of $5.94 and a 200 day moving average of $5.96. The stock’s market capitalization is $51.57 million.

ILLEGAL ACTIVITY WARNING: This article was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2016/11/30/vtv-therapeutics-inc-vtvt-downgraded-by-zacks-investment-research-to-hold.html.

Several large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its stake in shares of vTv Therapeutics by 7.6% in the third quarter. Bank of New York Mellon Corp now owns 21,278 shares of the company’s stock worth $153,000 after buying an additional 1,504 shares in the last quarter. BlackRock Investment Management LLC increased its stake in shares of vTv Therapeutics by 25.3% in the second quarter. BlackRock Investment Management LLC now owns 27,758 shares of the company’s stock worth $161,000 after buying an additional 5,596 shares in the last quarter. State Street Corp increased its stake in shares of vTv Therapeutics by 37.5% in the second quarter. State Street Corp now owns 84,222 shares of the company’s stock worth $488,000 after buying an additional 22,983 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in shares of vTv Therapeutics by 23.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 96,439 shares of the company’s stock worth $559,000 after buying an additional 18,112 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of vTv Therapeutics by 0.8% in the third quarter. Northern Trust Corp now owns 81,262 shares of the company’s stock worth $584,000 after buying an additional 622 shares in the last quarter. 12.41% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

5 Day Chart for NASDAQ:VTVT

Receive News & Stock Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related stocks with our FREE daily email newsletter.